Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT00707980

Major Depressive Disorder

COMPLETED PHASE3

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

NCT00694304

Major Depressive Disorder

COMPLETED PHASE3

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

NCT01152996

Depressive Disorder, Major

COMPLETED PHASE3

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

NCT01323478

Major Depressive Disorder

COMPLETED PHASE3

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT00735709

Major Depressive Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted in the US and in Europe and will include paediatric patients diagnosed with depressive or anxiety disorders of two age populations; children aged 7-11 years and adolescents of the age 12-17 years. It is an open study to allow pharmacokinetic (PK) sampling of all patients and four dose levels will be tested. Following lower initial doses for 2 to 6 days, the patients will be treated once daily at the assigned dose levels for 14 days, and it is expected that patients may benefit from treatment during this period. As the treatment duration is not sufficient according to treatment guidelines, if judged or indicated by the investigator, the patients are offered to continue in an extension treatment of up to six months to allow possibility for therapeutic satisfaction.

Preferably, the cohorts will be dosed in the following order: AC1, AC2, CC1, AC3, CC2, AC4, CC3, and CC4. An external data safety monitoring board (DSMB) will be established to evaluate safety, tolerability and preliminary PK data from the dosed cohort(s) prior to any dosing of subsequent cohort (s). The dose regimen may be adjusted based on the recommendation of the DSMB. Adolescents will be exposed to a certain dose of vortioxetine before children receive the same dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort CC1, 6 children

Group Type EXPERIMENTAL

Vortioxetine

Intervention Type DRUG

5 mg tablets for 14 days; orally; once daily

Cohort CC2, 6 children

Group Type EXPERIMENTAL

Vortioxetine

Intervention Type DRUG

10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily

Cohort CC3, 6 children

Group Type EXPERIMENTAL

Vortioxetine

Intervention Type DRUG

15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily

Cohort CC4, 6 children

Group Type EXPERIMENTAL

Vortioxetine

Intervention Type DRUG

20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily

Cohort AC1, 6 adolescents

Group Type EXPERIMENTAL

Vortioxetine

Intervention Type DRUG

5 mg tablets for 14 days; orally; once daily

Cohort AC2, 6 adolescents

Group Type EXPERIMENTAL

Vortioxetine

Intervention Type DRUG

10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily

Cohort AC3, 6 adolescents

Group Type EXPERIMENTAL

Vortioxetine

Intervention Type DRUG

15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily

Cohort AC4, 6 adolescents

Group Type EXPERIMENTAL

Vortioxetine

Intervention Type DRUG

20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vortioxetine

5 mg tablets for 14 days; orally; once daily

Intervention Type DRUG

Vortioxetine

10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily

Intervention Type DRUG

Vortioxetine

15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily

Intervention Type DRUG

Vortioxetine

20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brintellix Brintellix Brintellix Brintellix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder.
* The patient and parent(s)/legal representative(s) are able to comprehend and satisfactorily comply with the protocol requirements.
* Treatment with antidepressant therapy is warranted, as judged by the investigator.

Exclusion Criteria

* The patient is pregnant or breast-feeding.
* The patient presents or has a history of an Axis I (DSM-IV-TR) diagnosis of Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Autism, Pervasive Developmental Disorder (PDD), Obsessive Compulsive Disorder (OCD) or Schizophrenia or Schizoaffective Disorder.
* The patient has not maintained a stable dose of a methylphenidate or amphetamine for their treatment of attention-deficit/hyperactivity disorder (ADHD) for a minimum of 4 weeks prior to the study treatment.
* The patient has a known mental retardation, or clinical evidence or known social or school history indicative of mental retardation.
* The patient is at significant risk of committing suicide based on history (for example previous suicide attempt) or according to the investigator's experience, or based on active suicidal ideation, intent or plan, item 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS).
* The subject has any concurrent illness that may affect the particular target or absorption, distribution, and elimination of the investigational medicinal product (IMP).
* The patient meets DSM-IV-TR criteria for any psychoactive substance or alcohol use disorder.

Minimum Eligible Age

7 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No